Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.62 |
| ▸ | TMIGD3 | P0DMS9 | 9/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210251 | 0.97 | TLR7 (0.58) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL7208663 | 0.93 | TMIGD3 (0.57) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL15726062 | 0.91 | TLR7 (0.53) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL4473247 | 0.90 | TLR7 (0.54) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL10310084 | 0.89 | TLR7 (0.54) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL4462086 | 0.89 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL15398270 | 0.89 | TLR7 (0.52) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL15242267 | 0.89 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL4460913 | 0.89 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL7206459 | 0.89 | TMIGD3 (0.54) | TLR7TMIGD3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-9884112-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884112-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9006254-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006254-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | TLR7 41/4885TMIGD3 2577/4885ADORA2A 1537/4885 |
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | CD47, MSR1, CD14 | TLR7 118/4885TMIGD3 3601/4885ADORA2A 1230/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | TLR7 31/4885TMIGD3 3870/4885ADORA2A 11/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | TLR7 4/4885TMIGD3 3431/4885ADORA2A 61/4885 |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | TLR7 41/4885TMIGD3 2577/4885ADORA2A 1537/4885 |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | CD47, IFNG, TSLP | TLR7 31/4885TMIGD3 3035/4885ADORA2A 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.